Ulcerative Colitis Flare Clinical Trial
Official title:
Screening Donors for a Fecal Microbiota Transplant Program in Ulcerative Colitis: Evaluating Efficacy and Long-term Effects. The FUEL Study
The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.
This is an open label study with all UC patients receiving FMT. Up to 200 patients with active UC will be recruited to the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05466890 -
Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)
|
Phase 2 | |
| Recruiting |
NCT05680883 -
Local and Systemic Immunoprofiling of Patients Diagnosed With Ulcerative Colitis
|
||
| Not yet recruiting |
NCT04276740 -
MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis
|
Phase 2 | |
| Recruiting |
NCT03798210 -
Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis
|
Phase 2 | |
| Recruiting |
NCT05998213 -
Transfer of Feces in Ulcerative Colitis 2
|
Phase 2 |